34 results about "Vasodilator stress" patented technology

A composition for topical application comprising a therapeutically effective amount of a topical anesthetic, a safe and effective amount of a pharmaceutically acceptable topical vasodilator and a pharmaceutically acceptable carrier and a method of administering the composition to a mammal are disclosed.

A rapid acting injectable formulation is provided comprising a therapeutic peptide and a vasodilatory agent. The therapeutic peptide has a molecular weight of greater than about 500 Daltons, and the vasodilatory agent is present in an amount effective to increase the absorption of the therapeutic peptide. A method of increasing absorption of a therapeutic peptide by using such a formulation is also provided.

Novel derivatives of isosorbide mononitrate and its pharmaceutically acceptable salts, which have vasodilating activity with a reduced effect of tolerance, of the general formula (I) in which A and B independently represent any of the groups—ONO2 and —Z—CO—R, wherein Z is an oxygen atom or sulphur atom and R is an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, or the group in which R1 is hydrogen, or an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, with the proviso that one of A or B is always —ONO2, but never both of them at the same time, when Z is an sulphur atom R is an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, and when Z is an oxygen atom R is the group

Compositions for protection against SVFS induced by niacin, a carcinoid, mesenteric traction, serotonin, post-menopause, alcohol, monosodium glutamate, mastocytosis, atopic dermatitis, food-allergy or food intolerance, and mast cell activation syndrome, or against individual symptoms of SVFS, superficial vasodilation, feeling of warmth, itching (pruritus) and hives, comprising a flavonoid compound of the structure 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, or chalconoid compounds, with appropriate substitutions of their hydroxyl groups to render them water soluble or in combination with a pshospholipid or cyclodextrin to render them to have higher oral absorption, administered alone or together with an anti-superficial vasodilation dose of one or more of, olive kernel oil, a serotonin inhibitor, a prostaglandin inhibitor, willow bark extract. A composition for treating cardiovascular disease with niacin, but without eliciting the SVFS effects of niacin, has also been invented.

This invention describes the simultaneous or sequential administration of therapeutic or diagnostic agents using different devices in combination with a chemical formulation that incorporates or uses vasomodulatory chemical agents as part of the drug delivery vehicle. Methods include the addition of various vasodilatory and vasoconstrictive agents to enhance the systemic or localized tissue delivery of therapeutic or diagnostic agents delivered into a body through the use of an apparatus or device.

A method, composition, and kit for topical application of a composition to a male penis to delay premature ejaculation during intercourse without adversely affecting response in a female partner are disclosed. The method includes applying to the penis a topical composition immediately prior to intercourse. The composition includes an effective amount of a vasodilator agent and a desensitizing agent such as an acetyl dipeptide-1 cetyl ester.

The present invention relates to a planar-shaped drug preparation that quickly dissolves or decomposes in an aqueous environment, for the application of active ingredient combinations for the treatment of hypertension, wherein the drug preparations contain at least two active ingredients that are suitable for the treatment of hypertension, and wherein the antihypertensive drug is selected from the group that encompasses beta receptor blockers, alpha receptor blockers, calcium antagonists, ACE inhibitors, AT1 antagonists, centrally acting antihypertensive drugs, direct vasodilators, and diuretics. The present invention also relates to the use of active ingredient combinations according to the invention for the production of an oral drug preparation for the treatment of high blood pressure, to a method for the therapeutic treatment of hypertension, and to a method for the production of a planar-shaped drug preparation.

Provided are methods and compositions for locally increasing arterial diameter and providing local anesthesia in a subject. The methods include applying to a skin site of the subject a topical composition that includes a vasodilation agent and an anesthetic agent in a manner sufficient for locally increasing arterial diameter and providing local anesthesia in the subject. In some embodiments, the method includes inserting a cannula into an artery at the skin site of the subject. Also provided are topical compositions that find use in performing the subject methods.

A method and a device are disclosed for transdermal delivery to an animal or human of biological cargo-laden nanoparticles. The particles may include multimodal optical molecular imaging probes. The particles may be delivered by providing them in a form that can be absorbed through the skin and applying them to the skin of an animal or human. The application may be accomplished using biological cargo-laden nanoparticles in a device attachable to the skin. The device may be attached directly to the skin by a device containing a vasodilating agent or agents, or micro needles, or multi-layer time release material. The biological cargo-laden nanoparticles may comprise drugs, vaccines, bio-pharmaceuticals, imaging contrast agents, multimodal imaging contrast agents, biomolecules, or anti-infectives. The device may include a first plurality of different types of biological cargo-laden nanoparticles located in a corresponding second plurality of separate time release layers.

The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).

The invention discloses application of patchouli alcohol in preparation of an endothelium-independent vasodilator. The invention further discloses a medicine for treating cardiovascular and cerebrovascular diseases caused by endothelial injury. The medicine is a preparation prepared from patchouli alcohol serving as an active ingredient and pharmaceutically acceptable excipients or auxiliary components. The patchouli alcohol has an endothelium-independent vasodilation effect, and has clinical significances for treating the cardiovascular and cerebrovascular diseases.

Compositions, devices and methods for the transdermal delivery of drugs that are potent vasorelaxants and inhibitors of human platelet aggregation are disclosed. These drugs bind to the IP receptor on endothelial and platelet cells and they are useful in the treatment of pulmonary arterial hypertension and other diseases where vasoconstriction is an issue. The compositions, methods and devices pertain particularly to the transdermal delivery of the selexipag metabolite ACT 333679.

The present invention relates to pharmaceutical compositions containing targetable bioconjugates of hydralazine, a direct vasodilating agent previously shown to decrease tumor blood flow, oxygenation and interstitial fluid pressure in solid tumors. These bioconjugates are hydralazine prodrugs that contain hydralazine conjugated to biocompatible carrier molecules which specifically bind to sites that are expressed on a diverse variety of tumor cell types. These hydralazine prodrugs are preferably conjugated through an acid-labile hydrazone link that is designed to be stable in plasma and release hydralazine through acid-catalyzed hydrolysis in the acidic environment of the target tumor. Because these prodrugs are stable at physiological pH and in plasma, they are devoid of systemic vasoactive activity; however, they are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor where the vasoactive activity of hydralazine is restored. These prodrugs selectively bind to tumor-specific receptors on tumor cells, and are degraded in the acidic tumor cell environment or the acidic lysosomal compartments after being internalized into the cell.

The invention relates to a method for preparing pterocarpus santalinus ethanol extract used for endothelium-dependent vasodilator and applications of the extract on the medicine or health products of endothelium-independent vasodilator. The preparation method comprises the steps of extracting the pterocarpus santalinus powders thrice in a back-flow way by 70% of ethanol of 6 times, 5 times and 3 times respectively for 2.5h, 2h and 1.5h, decompressing, concentrating, cooling and drying the extract, and finally obtaining the pterocarpus santalinus extract. Suitable auxiliary material is added into the pterocarpus santalinus extract so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.

The invention is directed to improved methods for modulating the human sexual response by orally administering a vasodilator to the blood circulation, thereby modulating the sexual response on demand.

Apparatus and methods are disclosed for inserting electrical leads within a heart. In one aspect of the present invention, a method for positioning a medical electrical lead in a cardiac vein is disclosed. The method comprises inserting a lead within a coronary sinus, dispersing at least one vasodilating agent to dilate at least one cardiac vein, and inserting the lead into a dilated cardiac vein.

The invention relates to a method for preparing pterocarpus santalinus water extract used as a non-endothelium-dependent vasodilation agent and applications of the extract on the medicines or health products of non-endothelium-dependent vasodilation agent. The preparation method comprises the steps of extracting the pterocarpus santalinus powders thrice by 70% of water circumfluence of 6 times, 5times and 3 times respectively for 2.5h, 2h and 1.5h, decompressing, concentrating, cooling and drying the extract, and finally obtaining the pterocarpus santalinus extract. Suitable auxiliary material is added into the obtained pterocarpus santalinus extract so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.

A method for treating noise-induced hearing loss (NIHL) includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and / or resveratrol.

Provided are methods and compositions for locally increasing arterial diameter and providing local anesthesia in a subject. The methods include applying to a skin site of the subject a topical composition that includes a vasodilation agent and an anesthetic agent in a manner sufficient for locally increasing arterial diameter and providing local anesthesia in the subject. In some embodiments, the method includes inserting a cannula into an artery at the skin site of the subject. Also provided are topical compositions that find use in performing the subject methods.

The invention relates to a method for preparing pterocarpus santalinus water extract used for endothelium-dependent vasodilator and applications of the extract on the medicine or health products of endothelium-independent vasodilatior. The preparation method comprises the steps of extracting the pterocarpus santalinus powders thrice in a back-flow way by 70% of water of 6 times, 5 times and 3 times respectively for 2.5h, 2h and 1.5h, decompressing, concentrating, cooling and drying the extract, and finally obtaining the pterocarpus santalinus extract. Suitable auxiliary material is added into the pterocarpus santalinus extract so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.

Semi-synthetic oximes derived from metabolites extracted from medicinal plants, Senecio nutans and Xenophyllum poposum, the method of preparation thereof and their use as agents with vasodilator and hypotensive effects are provided.

The invention relates to a method for preparing pterocarpus indicus ethanol extract used for non-endothelium-dependent vasodilation agent and applications of the extract on the medicines or health products of non-endothelium-dependent vasodilation agent. The preparation method comprises the steps of extracting the pterocarpus indicus powders thrice by 70% of ethanol circumfluence of 6 times, 5 times and 3 times respectively for about 2.5h, 2h and 1.5h, distilling and concentrating the extract by decompressing, cooling and drying the extract, and finally obtaining the pterocarpus indicus extract. Suitable auxiliary material is added into the obtained pterocarpus indicus extract in normal pharmacy method so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.

Semi-synthetic oximes derived from metabolites extracted from medicinal plants, Senecio nutans and Xenophyllum poposum, the method of preparation thereof and their use as agents with vasodilator and hypotensive effects are provided.

The invention discloses a method for extracting hematopoietic stem cells, and belongs to the technical field of the extraction of stem cells. The method comprises the steps that a placenta is flushedfrom the exterior with normal saline, 30 mL of an anticoagulant / vasodilator solution is injected at the room temperature; one end of a perfusate needle is inserted into the umbilical artery of the placenta, and the other end of the perfusate needle is inserted into a perfusion container; one end of a reflux liquid needle is inserted into the umbilical vein of the placenta, and the other end of thereflux liquid needle is inserted into the perfusion container to form a perfusion circuit; long-term lavage is carried out for 6 hours with a cell lavage fluid at a flow velocity of 5 drops per minute, and the first-time lavage fluid is collected; lavage is carried out for 30 minutes with the cell lavage fluid at a flow velocity of 5 drops per minute, and the second-time lavage fluid is collected; the first-time lavage fluid and the second-time lavage fluid are mixed to collect the cells, and DMSO is added and mixed with a dextran cell cryoprotectant for cryopreservation. The method for extracting the hematopoietic stem cells has the advantages that the viability is high, and the proportion of CD34+ cells is high.

Provided is a vasorelaxant from food that has few side effects and is safe for hypertension patients and healthy persons said to have prehypertension. Also provided are foods and beverages including this composition and foods and beverages such as health foods, functional foods, and health supplements. An extract of yeast is used as an active ingredient. A yeast extract obtained by a simple procedure consisting of hot-water treatment, acid or alkali treatment, and enzyme treatment of yeast was discovered to have a superior vasorelaxing effect as a yeast extract.

The invention relates to a method for preparing pterocarpus santalinus water extract used for endothelium-dependent vasodilator and applications of the extract on the medicine or health products of endothelium-independent vasodilatior. The preparation method comprises the steps of extracting the pterocarpus santalinus powders thrice in a back-flow way by 70% of water of 6 times, 5 times and 3 times respectively for 2.5h, 2h and 1.5h, decompressing, concentrating, cooling and drying the extract, and finally obtaining the pterocarpus santalinus extract. Suitable auxiliary material is added into the pterocarpus santalinus extract so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.

The invention relates to a method for preparing pterocarpus indicus ethanol extract used for non-endothelium-dependent vasodilation agent and applications of the extract on the medicines or health products of non-endothelium-dependent vasodilation agent. The preparation method comprises the steps of extracting the pterocarpus indicus powders thrice by 70% of ethanol circumfluence of 6 times, 5 times and 3 times respectively for about 2.5h, 2h and 1.5h, distilling and concentrating the extract by decompressing, cooling and drying the extract, and finally obtaining the pterocarpus indicus extract. Suitable auxiliary material is added into the obtained pterocarpus indicus extract in normal pharmacy method so as to prepare the medicines or health products such as powder injection, drops, troche, capsule, oral liquid, grain agents and the like.

The invention discloses the application of buccal alcohol in the preparation of an endothelium-independent vasodilator. The invention also discloses a medicament for treating cardiovascular and cerebrovascular diseases caused by endothelial injury, which is a preparation prepared by using bocicol as an active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients. The pottyrae alcohol of the present invention has a vasodilation effect independent of the endothelium, and has great clinical significance for the treatment of cardiovascular and cerebrovascular diseases.